Charles River Laboratories International Aktie

145,88 EUR +1,22 EUR +0,84 %

27.04.2026

BMN

171,23 USD +1,37 USD +0,81 %

27.04.2026

BTT

Charles River Laboratories International jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.7,15 Mrd. EUR

Div. Rendite0,00%

WKN939391

ISINUS1598641074

SymbolCRL

Charles River Laboratories International Aktien News

Sortieren:Datum Meistgelesen

16.01.25BusinesswireCharles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

13.01.25BusinesswireCharles River Laboratories to Present at J.P. Morgan Healthcare Conference

05.12.24BusinesswireCharles River Introduces Global Biotech Incubator Program

WerbungCharles River Laboratories International-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

02.12.24BusinesswireCharles River Laboratories to Present at Evercore ISI Investor Conference

17.10.24BusinesswireCharles River Launches New Retrogenix® Non-Human Protein Library

16.10.24BusinesswireCharles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

03.10.24BusinesswireCharles River Provides Translational Expertise at Neuroscience 2024

02.10.24BusinesswireCharles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

17.09.24BusinesswireCharles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

04.09.24PR NewswireCharles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

04.09.24BusinesswireCharles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

03.09.24BusinesswireCharles River Laboratories to Present at Baird and Morgan Stanley Conferences

30.07.24BusinesswireCharles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development

24.07.24BusinesswireCharles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

16.07.24BusinesswireCharles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call

08.07.24BusinesswireCharles River to Perform Plasmid Manufacturing for AAVantgarde

25.06.24BusinesswireCharles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus

17.06.24BusinesswireCharles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

11.06.24BusinesswireCharles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives

06.06.24BusinesswireCharles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville

04.06.24BusinesswireCharles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research

03.06.24BusinesswireCharles River Laboratories to Present at William Blair and Jefferies Conferences

30.05.24BusinesswireCharles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development

02.05.24BusinesswireCharles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP

22.04.24BusinesswireCharles River Laboratories Achieves 100% Renewable Electricity Usage Globally

16.04.24BusinesswireCharles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

12.04.24BusinesswireCharles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call

11.04.24BusinesswireCharles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

09.04.24BusinesswireCharles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

04.04.24BusinesswireCharles River to Perform Plasmid Production for Ship of Theseus

01.04.24BusinesswireCharles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024

27.03.24BusinesswireCharles River Laboratories Publishes 2023 Corporate Citizenship Report

21.03.24BusinesswireCharles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine

14.03.24BusinesswireCharles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

12.03.24BusinesswireCharles River Laboratories to Present at Barclays Global Healthcare Conference

29.02.24PR NewswireWheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

21.02.24BusinesswireCharles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

20.02.24BusinesswireCharles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

29.01.24BusinesswireCharles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test

Charles River Laboratories International News

Charles River Laboratories International News: auf dieser Seite finden Sie alle Charles River Laboratories International News und Nachrichten zur Charles River Laboratories International Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Charles River Laboratories International News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Charles River Laboratories International News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.